Dr. Tamara Ranalli is responsible for defining and executing the strategic vision for the QuidelOrtho molecular and point-of-care diagnostics portfolios. She leads the management of all functions of the business unit in all regions and is accountable for growing revenue and market share worldwide.

Dr. Ranalli joined Quidel in 2010 as an Associate Director for molecular program management. Previous to her current position, she held several key roles including Vice President of Marketing and Senior Vice President of the molecular business unit. During the COVID-19 pandemic, she was instrumental in the successful launch of the Sofia® SARS-CoV-2 Antigen Assay, as well as the Lyra® and Solana® SARS-CoV-2 Molecular Assays. She also recently spearheaded the launch of the Savanna® Instrument, the company’s flagship molecular sample-to-result testing platform.

Dr. Ranalli received a bachelor’s degree in biology from Cornell University and completed her master’s and PhD in biochemistry at University of Rochester School of Medicine.